Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works

Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations

Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650 · see citing works

Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease

Ibáñez, P., Bonnet, A. M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,042 · see citing works

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · see citing works

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

Reiber, H., & Peter, J. B. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00501-3 · Cited by 740 · see citing works

Errors in clinical laboratories or errors in laboratory medicine?

Plebani, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.123 · Cited by 737 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

Mollenhauer, B., Locascio, J. J., Schulz‐Schaeffer, W., Sixel‐Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 623 · see citing works

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works

Dynamics of brain-derived proteins in cerebrospinal fluid

Reiber, H. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00573-3 · Cited by 512 · see citing works

Protein Stability During Freezing: Separation of Stresses and Mechanisms of Protein Stabilization

Bhatnagar, B. S., Bogner, R. H., & Pikal, M. J. (2007) · Pharmaceutical Development and Technology · doi:10.1080/10837450701481157 · Cited by 483 · see citing works

Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy

Nishino, S., Ripley, B. A., Overeem, S., Nevšímalová, S., Lammers, G. J., Vaňková, J., Okun, M. L., Rogers, W. M., Brooks, S. N., & Mignot, E. J.-M. (2001) · Annals of Neurology · doi:10.1002/ana.1130 · Cited by 451 · see citing works

Tau and Aβ42 in Cerebrospinal Fluid from Healthy Adults 21–93 Years of Age: Establishment of Reference Values

Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436 · see citing works

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Mattsson, N., Andréasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2243 · Cited by 409 · see citing works

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358 · see citing works

Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 332 · see citing works

Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker

Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260 · see citing works

Post‐lumbar puncture headaches

Kuntz, K. M., Kokmen, E., Stevens, J. C., et al. (1992) · Neurology · doi:10.1212/wnl.42.10.1884 · Cited by 242 · see citing works

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H. S., Anckarsäter, R., Andreasen, N., Zetterberg, H., Andréasson, U., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/986310 · Cited by 233 · see citing works

Reelin expression and glycosylation patterns are altered in Alzheimer’s disease

Botella-López, A., Burgaya, F., Gavín, R., García-Ayllón, M. S., Gómez-Tortosa, E., Peña-Casanova, J., Ureña, J. M., Del Río, J. A., Blesa, R., Soriano, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601279103 · Cited by 221 · see citing works

Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., Carlo, C. D., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 170 · see citing works

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C. M., Sokolow, S., Deyn, P. P. D., Galasko, D. R., Hampel, H. J., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 169 · see citing works

Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid

Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & Bruijn, C. D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 167 · see citing works

Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice

Schoonenboom, N. S. M., Mulder, C., Vanderstichele, H., van Elk, E.-J., Kok, A., van Kamp, G. J., Scheltens, P., & Blankenstein, M. A. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039735 · Cited by 165 · see citing works

Sample Handling for Mass Spectrometric Proteomic Investigations of Human Sera

West-Nielsen, M., Høgdall, E. V. S., Marchiori, E., Høgdall, C. K., Schou, C., & Heegaard, N. H. H. (2005) · Analytical Chemistry · doi:10.1021/ac050253g · Cited by 144 · see citing works

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides

Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 143 · see citing works

The impact of blood contamination on the proteome of cerebrospinal fluid

You, J., Gelfanova, V., Knierman, M. D., et al. (2004) · PROTEOMICS · doi:10.1002/pmic.200400889 · Cited by 121 · see citing works

Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121 · see citing works

The Effect of Preanalytical Factors on Stability of the Proteome and Selected Metabolites in Cerebrospinal Fluid (CSF)

Rosenling, T., Slim, C. L., Christin, C., et al. (2009) · Journal of Proteome Research · doi:10.1021/pr9005876 · Cited by 119 · see citing works

Quantification of α-Synuclein in Cerebrospinal Fluid As a Biomarker Candidate: Review of the Literature and Considerations for Future Studies

Mollenhauer, B., El‐Agnaf, O. M. A., Marcus, K., Trenkwalder, C., & Schlossmacher, M. G. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.90 · Cited by 114 · see citing works

Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ß-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas

Fortea, J., Sala‐Llonch, R., David Bartrés-faz, A., Lladó, A., Solé‐Padullés, C., Bosch, B., Antonell, A., Olives, J., Sánchez‐Valle, R., Molinuevo, J. L., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.017 · Cited by 111 · see citing works

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

Perret‐Liaudet, A., Pelpel, M., Tholance, Y., Dumont, B., Vanderstichele, H., Zorzi, W., Elmoualij, B., Schraen‐Maschke, S., Moreaud, O., Gabelle, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120361 · Cited by 108 · see citing works

Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat

Murillo‐Rodríguez, E., Désarnaud, F., & Prospero-Garcia, O. E. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.028 · Cited by 107 · see citing works

International quality control survey of neurochemical dementia diagnostics

Lewczuk, P., Beck, G., Ganslandt, O., Esselmann, H., Deisenhammer, F., Regeniter, A., Petereit, H.-F., Tumani, H., Gerritzen, A., Oschmann, P., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.009 · Cited by 98 · see citing works

Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides

Bibl, M., Esselmann, H., Otto, M., Lewczuk, P., Cepek, L., Rüther, E., Kornhuber, J., & Wiltfang, J. (2004) · Electrophoresis · doi:10.1002/elps.200305992 · Cited by 91 · see citing works

Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process?

Carrette, O., Burkhard, P. R., Hughes, S., Hochstrasser, D. F., & Sanchez, J. (2005) · PROTEOMICS · doi:10.1002/pmic.200402039 · Cited by 83 · see citing works

Protein Analyses in Cerebrospinal Fluid

Blennow, K., Fredman, P., Wallin, A., Gottfries, C., Långström, G., & Svennerholm, L. T. (2008) · European Neurology · doi:10.1159/000116918 · Cited by 81 · see citing works

Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation

Chaigneau, C., Cabioch, T., Beaumont, K., & Betsou, F. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.160 · Cited by 78 · see citing works

Toward an Alzheimer's disease diagnosis via high‐resolution blood gene expression

Fehlbaum, P., Prado, A. C. J.-L., Pallares, D., Carrière, J., Guihal, C., Soucaille, C., Rouet, F., Drouin, D., Sol, O., Jordan, H. M., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.001 · Cited by 75 · see citing works

α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system

Mollenhauer, B., Trautmann, E., Otte, B., Ng, J., Spreer, A., Lange, P., Sixel‐Döring, F., Hakimi, M., Vonsattel, J., Nussbaum, R. L., et al. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0784-0 · Cited by 75 · see citing works

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β(1-42) , Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

Teunissen, C. E., Verwey, N. A., Kester, M. I., van Uffelen, K. W. J., & Blankenstein, M. A. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/635053 · Cited by 70 · see citing works

A Novel Blood Test for the Early Detection of Alzheimer's Disease

Rye, P. D., Booij, B. B., Grave, G., Lindahl, T., Kristiansen, L., Andersen, H., Horndalsveen, P. O., Nygaard, H. A., Naik, M., Hoprekstad, D., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101521 · Cited by 69 · see citing works

Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease

Rami, L., Sala‐Llonch, R., Solé‐Padullés, C., Fortea, J., Olives, J., Lladó, A., Peña-Gómez, C., Balasa, M., Bosch, B., Antonell, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120223 · Cited by 68 · see citing works

Serum S100B Protein Is Increased in Fasting Rats

Netto, C. B. O., Conte, S., Leite, M. C., Pires, C., Martins, T. L., Vidal, P. R., Benfato, M. S., Giugliani, R., & Gonçalves, C. (2006) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.11.005 · Cited by 64 · see citing works

From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease

Zheng, H., Amit, T., Bar‐Am, O., Fridkin, M., Youdim, M. B. H., & Mandel, S. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120013 · Cited by 61 · see citing works

Pre‐analytical influence on the low molecular weight cerebrospinal fluid proteome

Berven, F. S., Kroksveen, A. C., Berle, M., Rajalahti, T., Flikka, K., Arneberg, R., Myhr, K., Vedeler, C. A., Kvalheim, O. M., & Ulvik, R. J. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700126 · Cited by 60 · see citing works

Preanalytical Sample Handling and Sample Stability Testing for the Neurochemical Dementia Diagnostics

Zimmermann, R., Lelental, N., Ganslandt, O., Maler, J. M., Kornhuber, J., & Lewczuk, P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110212 · Cited by 56 · see citing works

Spectrophotometry for Cerebrospinal Fluid Pigment Analysis

Petzold, A., Sharpe, L. T., & Keir, G. (2006) · Neurocritical Care · doi:10.1385/ncc:4:2:153 · Cited by 53 · see citing works

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease

Mattsson, N., Zetterberg, H., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/610613 · Cited by 49 · see citing works

Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers

Slats, D., Claassen, J. A. H. R., Spies, P. E., Borm, G. F., Besse, K., van Aalst, W., Tseng, J., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.07.008 · Cited by 48 · see citing works

Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid

Blennow, K., Wallin, A., Gottfries, C. G., Månsson, J., & Svennerholm, L. T. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260910 · Cited by 46 · see citing works

Cerebrospinal Fluid Aβ and Tau Level Fluctuation in an Older Clinical Cohort

Moghekar, A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.732 · Cited by 46 · see citing works

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20

Pica-Mendez, A. M., Tanen, M., Dallob, A. L., Tanaka, W. K., & Laterza, O. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.019 · Cited by 43 · see citing works

Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1–42)

Kaiser, E., Schönknecht, P., Thomann, P. A., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.02.045 · Cited by 43 · see citing works

Endogeneous peptide profiling of cerebrospinal fluid by MALDI‐TOF mass spectrometry: Optimization of magnetic bead‐based peptide capture and analysis of preanalytical variables

Jiménez, C. R., Simmelink, M. J. A., Pham, T. V., van der Voort, L. F., & Teunissen, C. E. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700330 · Cited by 37 · see citing works

Alzheimer’s disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications

Ho, L., Fivecoat, H. C., Wang, J., & Pasinetti, G. M. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.09.007 · Cited by 37 · see citing works

Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid

Kruse, N., Schulz‐Schaeffer, W., Schlossmacher, M. G., & Mollenhauer, B. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.016 · Cited by 34 · see citing works

Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid

Schipke, C. G., Jessen, F., Teipel, S. J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110329 · Cited by 32 · see citing works

Proteomic investigations of the ventriculo-lumbar gradient in human CSF

Simonsen, A. H., Bech, S., Laursen, I., Salvesen, L., Winge, K., Waldemar, G., Werdelin, L., Nielsen, J. E., McGuire, J. N., & Hjermind, L. E. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.06.017 · Cited by 27 · see citing works

Recommandations préanalytiques pour les analyses de protéomique clinique des fluides biologiques

Lehmann, S., Roche, S., Allory, Y., et al. (2009) · Annales de biologie clinique · doi:10.1684/abc.2009.0374 · Cited by 17 · see citing works

CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans

Spies, P. E., Slats, D., Rikkert, M. G. M. O., Tseng, J., Claassen, J. A. H. R., & Verbeek, M. M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.09.063 · Cited by 12 · see citing works

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651 · see citing works

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163 · see citing works

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Gobom, J., Parnetti, L., Rosa-Neto, P., Vyhnalek, M., Gauthier, S., Cataldi, S., Lerch, O., Laczo, J., Cechova, K., Clarin, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0651 · Cited by 146 · see citing works

Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression

Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C., Wall, A. E., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001209 · Cited by 142 · see citing works

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum

Meeter, L. H. H., Vijverberg, E. G., Del Campo, M., Rozemuller, A. J. M., Donker Kaat, L., de Jong, F. J., van der Flier, W. M., Teunissen, C. E., van Swieten, J. C., & Pijnenburg, Y. A. L. (2018) · Neurology · doi:10.1212/wnl.0000000000005261 · Cited by 122 · see citing works

New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52 · see citing works

C1q is increased in cerebrospinal fluid‐derived extracellular vesicles in Alzheimer's disease: A multi‐cohort proteomics and immuno‐assay validation study

Chatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47 · see citing works

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

Kruse, N., Persson, S., Alcolea, D., Bahl, J. M. C., Baldeiras, I., Capello, E., Chiasserini, D., Bocchio Chiavetto, L., Emersic, A., Engelborghs, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.003 · Cited by 38 · see citing works

Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays

del Campo, M., Jongbloed, W., Twaalfhoven, H. A. M., Veerhuis, R., Blankenstein, M. A., & Teunissen, C. E. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00202 · Cited by 34 · see citing works

Novel <scp>CSF</scp> biomarkers to discriminate <scp>FTLD</scp> and its pathological subtypes

del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y. A., van Swieten, J. C., Watts, K., Paciotti, S., Beccari, T., Hu, W., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.629 · Cited by 30 · see citing works

[Verification of guideline for gastric cancer treatment based on a questionnaire].

Sekikawa, K., Ohki, S., Kohunato, Y., et al. (2004) · PubMed

Evaluating the role of confounding in pharmacoeconomic studies.

Joish, V. N., & Sahai, A. (2003) · PubMed · Cited by 1 · see citing works

[The guideline for the treatment of mood disorders in USA and Japan].

Higuchi, T. (2001) · PubMed · Cited by 2 · see citing works

Chapters 6-7

(2003) · Thorax · doi:10.1136/thx.58.suppl_1.i32 · Cited by 1 · see citing works

INTRODUCING AN OPERATIVE AND SUPERVISION GUIDELINE FOR HIP FRACTURE SURGERY REDUCED THE RATE OF RE-OPERATION FROM 15% TO 10%

Palm, H., Krasheninnikoff, M., Holck, K., et al. (2010) · Orthopaedic Proceedings